Biodistribution of Neural Stem Cells After Intravascular Therapy for Hypoxic–Ischemia

Abstract

Background and Purpose Intravascular transplantation of neural stem cells represents a minimally invasive therapeutic approach for the treatment of central nervous system diseases. The cellular biodistribution after intravascular injection needs to be analyzed to determine the ideal delivery modality. We studied the biodistribution and efficiency of targeted central nervous system delivery comparing intravenous and intra-arterial (IA) administration of neural stem cells after brain ischemia. Methods Mouse neural stem cells were transduced with a firefly luciferase reporter gene for bioluminescence imaging (BLI). Hypoxic–ischemia was induced in adult mice and reporter neural stem cells were transplanted IA or intravenous at 24 hours after brain ischemia. In vivo BLI was used to track transplanted cells up to 2 weeks after transplantation and ex vivo BLI was used to determine single organ biodistribution. Results Immediately after transplantation, BLI signal from the brain was 12 times higher in IA versus intravenous injected animals (P<0.0001). After IA injection, 69% of the total luciferase activity arose from the brain early after transplantation and 93% at 1 week. After intravenous injection, 94% of the BLI signal was detected in the lungs (P = 0.004) followed by an overall 94% signal loss at 1 week, indicating lack of cell survival outside the brain. Ex vivo single organ analysis showed a significantly higher BLI signal in the brain than in the lungs, liver, and kidneys at 1 week (P<0.0001) and 2 weeks in IA (P = 0.007). Conclusion IA transplantation results in superior delivery and sustained presence of neural stem cells in the ischemic brain in comparison to intravenous infusion.

The Endogenous Regenerative Capacity of the Damaged Newborn Brain: Boosting Neurogenesis with Mesenchymal Stem Cell Treatment

“…136 Furthermore, efficacy of treatment may also depend on the administration route. Recently, it has been shown that intravenously injected mononuclear cells 137 and NSCs 138 are not only detected in the brain, but also in a substantial amount in the spleen, 137 and liver and lungs, respectively. 138 Hence, significantly less of the injected stem cells will end up in the brain after intravenous delivery as they will circulate throughout the body and may even have an undesired effect in other organs.…”

Treatment of the end Stage Liver Cirrhosis by Human Umbilical Cord Blood Stem Cells: Preliminary Results

“…Least effective method is mobilization from peripheral blood or bone marrow (170)(171) and most effective method is intracoronary infusion (172)(173). And in case of intravenous infusion, according to the blood flow, all blood in body has to pass the lung and some proportion of infused stem cells are trapped at the lung (174)(175). Some are trapped at other organs (176).…”

Stem cell therapies for neuropathic pain

“…However, this has not been supported by other studies on the biodistribution of NSCs following intravenous administration. 44 Finally, Franchi et al's study results are restricted to the chronic constriction injury model of peripheral neuropathic pain and cannot be extrapolated to other neuropathic pain models.…”